1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Novartis/Amgen End CNP520 Studies, Leaving Eisai/Biogen With Last BACE Inhibitor In The Clinic

 
• By Mandy Jackson

An interim look at two Phase II/III trials showed the drug worsened cognition in people at high risk of developing Alzheimer's disease. This is the 16th failure of a BACE-targeting therapy.

Alzheimers_677117191_Atthapon-Raksthaput_1200.jpg
Novartis and Amgen ended Phase II/III studies for BACE inhibitor CNP520. • Source: Shutterstock

Novartis AG and Amgen Inc. announced on 11 July that they have discontinued two Phase II/III clinical trials for CNP520 (umibecestat), a beta-site amyloid precursor protein-cleaving enzyme (BACE) inhibitor, in the prevention or delayed onset of Alzheimer's disease. The development makes Eisai Co. Ltd./Biogen's elenbecestat the only BACE inhibitor left in clinical testing for Alzheimer's disease after numerous prior failures for the class.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Pipeline Watch: Eight Approvals And Three Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors

 
• By Joseph Haas

The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.

Arbele Leverages Rights As It Drugs Proprietary CDH17 Target

 
• By Dexter Jie Yan

Arbele has emerged as a global leader in the Cadherin 17 area, not only in clinical progress but also for its “secret recipe” for application in T-cell engagers, its CEO tells Scrip.

Enhertu Takes The First-Line Throne In HER2 Metastatic Breast Cancer

 
• By Jessica Merrill

AstraZeneca and Daiichi’s DESTINY-Breast09 trial testing Enhertu with pertuzumab versus standard of care showed a statistically significant and meaningful PFS improvement.

More from R&D

Enhertu Takes The First-Line Throne In HER2 Metastatic Breast Cancer

 
• By Jessica Merrill

AstraZeneca and Daiichi’s DESTINY-Breast09 trial testing Enhertu with pertuzumab versus standard of care showed a statistically significant and meaningful PFS improvement.

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

 
• By Lisa Takagi

Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.